CLINICAL INVESTIGATION TO EVALUATE THE EFFICACY AND SAFETY OF EPILADY PROTOTYPE DEVICE FOLLOWED BY APPLICATION OF A TOPICAL FORMULA ON DEPIGMENTATION OF LENTIGO SPOTS

Inclusion Criteria: * Healthy female participants aged between 35 and 70 years old at the time of inclusion. * All Fitzpatrick skin phototypes (I to VI) are eligible; groups I-II and V-VI should include at least one participant per group. * Presence of at least two solar lentigo (dark spots) on each hand or forearm, with each spot measuring less than 100 mm x 100 mm as assessed by the investigator. * Participant has read, understood, and accepted the constraints of the clinical investigation. * Participant has provided written informed consent to participate in the clinical investigation. * Participant is able to understand the language used in the investigational site and comprehend the information provided. * Participants are cooperative and compliant, aware of the clinical investigation requirements and willing to adhere to the full duration of participation and follow-up visits, in line with the CIP requirements. * Women of childbearing potential must commit to using an effective contraceptive method throughout the clinical investigation period and for at least three months prior to the inclusion visit, with no changes during that time. Exclusion Criteria: * • Participants with dry or sensitive skin, as assessed by the investigator. * Participants who have used cosmetic products with exfoliating or astringent claims on the hands within 4 weeks prior to the baseline visit. * Participants who have used any home-use or professional low-level laser therapy (LLLT) or h…